Duopharma Biotech Bhd

Duopharma Biotech Bhd PEG

The PEG Ratio (Price/Earnings-to-Growth) of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 3, 2026 is 0.92.

PEG

0.92

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Duopharma Biotech Bhd is 2024 0.92 . PEG Ratio (Price/Earnings-to-Growth) of Duopharma Biotech Bhd was 2023 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

PEG Ratio (Price/Earnings-to-Growth) of Duopharma Biotech Bhd is 0.92 in 2024.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Duopharma Biotech Bhd with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd